---
document_datetime: 2025-12-02 05:40:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/respreeza.html
document_name: respreeza.html
version: success
processing_time: 0.1139763
conversion_datetime: 2025-12-28 18:03:22.269704
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Respreeza

[RSS](/en/individual-human-medicine.xml/66023)

##### Authorised

This medicine is authorised for use in the European Union

alpha1-proteinase inhibitor (human) Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Respreeza](#news-on)
- [More information on Respreeza](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Respreeza. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Respreeza.

For practical information about using Respreeza, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Respreeza and what is it used for?

Respreeza is a medicine used in adults with alpha 1 -proteinase inhibitor deficiency, an inherited disorder that can cause lung problems such as increasing shortness of breath and which may also affect the liver. Respreeza is used to slow down damage to the lungs in patients with severe disease.

Respreeza contains the active substance human alpha 1 -proteinase inhibitor.

## How is Respreeza used?

Respreeza is available as a powder and solvent to be made into a solution for infusion (drip) into a vein. The first infusion should be given under the supervision of a healthcare professional experienced in the treatment of alpha 1 -proteinase inhibitor deficiency. Subsequent infusions can be given by a caregiver or by the patient.

The recommended dose of Respreeza is 60 mg per kilogram body weight, given once a week. The infusion should last around 15 minutes.

The medicine can only be obtained with a prescription. For further information, see the package leaflet.

## How does Respreeza work?

The active substance in Respreeza, human alpha 1 -proteinase inhibitor, is a natural protein in the blood which protects lung tissue from damage. It is obtained from human blood and works by replacing the protein that is lacking in patients with alpha 1 -proteinase inhibitor deficiency.

## What benefits of Respreeza have been shown in studies?

Respreeza has been shown to slow down lung damage in one main study involving 180 patients with lung damage due to alpha 1 -proteinase inhibitor deficiency. In the study, Respreeza was compared with placebo (a dummy treatment) and the main measure of effectiveness was the decrease in lung density. Lung density is an indicator of the extent of lung damage: the bigger the decrease in lung density, the greater is the damage to the lung. The decrease in lung density after 24 months was around 2.6 g/l in patients who received Respreeza, compared with a decrease of around 4.2 g/l in patients receiving placebo.

## What are the risks associated with Respreeza?

The most common side effects with Respreeza (which may affect up to 1 in 10 people) are dizziness, headache, dyspnoea (shortness of breath) and nausea. Allergic reactions have been observed during treatment, some of which were severe.

Because of the risk of severe allergic reactions, Respreeza must not be used in patients who are lacking IgA, a protein in the blood, and who have developed antibodies against it because these patients are more prone to allergic reactions. For the full list of all side effects and restrictions with Respreeza, see the package leaflet.

## Why is Respreeza approved?

The main study with Respreeza showed that the medicine is effective at slowing down the damage to the lungs in patients with alpha 1 -proteinase inhibitor deficiency, and this effect is considered relevant for patients with severe disease. Allergic reactions were the main safety concern with Respreeza, but advice on how to manage this risk has been included in the product information. No other major concerns have been identified about the safety of the medicine.

Therefore, the Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Respreeza's benefits are greater than its risks and recommended that it be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Respreeza?

The company that markets Respreeza will carry out a further study to assess whether an increased dose of 120 mg/kg may lead to improved effects compared with the currently recommended dose.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Respreeza have also been included in the summary of product characteristics and the package leaflet.

## Other information about Respreeza

The European Commission granted a marketing authorisation valid throughout the European Union for Respreeza on 20 August 2015.

For more information about treatment with Respreeza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Respreeza : EPAR - Summary for the public

English (EN) (76.69 KB - PDF)

**First published:** 16/09/2015

**Last updated:** 03/10/2016

[View](/en/documents/overview/respreeza-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-384)

български (BG) (102.5 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/bg/documents/overview/respreeza-epar-summary-public_bg.pdf)

español (ES) (75.56 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/es/documents/overview/respreeza-epar-summary-public_es.pdf)

čeština (CS) (100.07 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/cs/documents/overview/respreeza-epar-summary-public_cs.pdf)

dansk (DA) (74.9 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/da/documents/overview/respreeza-epar-summary-public_da.pdf)

Deutsch (DE) (76.2 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/de/documents/overview/respreeza-epar-summary-public_de.pdf)

eesti keel (ET) (74.42 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/et/documents/overview/respreeza-epar-summary-public_et.pdf)

ελληνικά (EL) (104.06 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/el/documents/overview/respreeza-epar-summary-public_el.pdf)

français (FR) (76.3 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/fr/documents/overview/respreeza-epar-summary-public_fr.pdf)

hrvatski (HR) (96.28 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/hr/documents/overview/respreeza-epar-summary-public_hr.pdf)

italiano (IT) (75.56 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/it/documents/overview/respreeza-epar-summary-public_it.pdf)

latviešu valoda (LV) (97.38 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/lv/documents/overview/respreeza-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.85 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/lt/documents/overview/respreeza-epar-summary-public_lt.pdf)

magyar (HU) (94.12 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/hu/documents/overview/respreeza-epar-summary-public_hu.pdf)

Malti (MT) (101.22 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/mt/documents/overview/respreeza-epar-summary-public_mt.pdf)

Nederlands (NL) (74.88 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/nl/documents/overview/respreeza-epar-summary-public_nl.pdf)

polski (PL) (101.78 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/pl/documents/overview/respreeza-epar-summary-public_pl.pdf)

português (PT) (75.76 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/pt/documents/overview/respreeza-epar-summary-public_pt.pdf)

română (RO) (97.43 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/ro/documents/overview/respreeza-epar-summary-public_ro.pdf)

slovenčina (SK) (101.22 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/sk/documents/overview/respreeza-epar-summary-public_sk.pdf)

slovenščina (SL) (94.13 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/sl/documents/overview/respreeza-epar-summary-public_sl.pdf)

Suomi (FI) (74.93 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/fi/documents/overview/respreeza-epar-summary-public_fi.pdf)

svenska (SV) (75.31 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

03/10/2016

[View](/sv/documents/overview/respreeza-epar-summary-public_sv.pdf)

Respreeza : EPAR - Risk-management-plan summary

English (EN) (93.96 KB - PDF)

**First published:** 16/09/2015

**Last updated:** 16/09/2015

[View](/en/documents/rmp-summary/respreeza-epar-risk-management-plan-summary_en.pdf)

## Product information

Respreeza : EPAR - Product Information

English (EN) (533.83 KB - PDF)

**First published:** 16/09/2015

**Last updated:** 27/03/2025

[View](/en/documents/product-information/respreeza-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-2)

български (BG) (767.88 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/bg/documents/product-information/respreeza-epar-product-information_bg.pdf)

español (ES) (1.13 MB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/es/documents/product-information/respreeza-epar-product-information_es.pdf)

čeština (CS) (759.7 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/cs/documents/product-information/respreeza-epar-product-information_cs.pdf)

dansk (DA) (673.87 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/da/documents/product-information/respreeza-epar-product-information_da.pdf)

Deutsch (DE) (664.49 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/de/documents/product-information/respreeza-epar-product-information_de.pdf)

eesti keel (ET) (551.05 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/et/documents/product-information/respreeza-epar-product-information_et.pdf)

ελληνικά (EL) (632.33 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/el/documents/product-information/respreeza-epar-product-information_el.pdf)

français (FR) (654.9 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/fr/documents/product-information/respreeza-epar-product-information_fr.pdf)

hrvatski (HR) (1022.93 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/hr/documents/product-information/respreeza-epar-product-information_hr.pdf)

íslenska (IS) (649.9 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/is/documents/product-information/respreeza-epar-product-information_is.pdf)

italiano (IT) (648.77 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/it/documents/product-information/respreeza-epar-product-information_it.pdf)

latviešu valoda (LV) (709.68 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/lv/documents/product-information/respreeza-epar-product-information_lv.pdf)

lietuvių kalba (LT) (687.63 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/lt/documents/product-information/respreeza-epar-product-information_lt.pdf)

magyar (HU) (1.11 MB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/hu/documents/product-information/respreeza-epar-product-information_hu.pdf)

Malti (MT) (811.08 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/mt/documents/product-information/respreeza-epar-product-information_mt.pdf)

Nederlands (NL) (781.72 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/nl/documents/product-information/respreeza-epar-product-information_nl.pdf)

norsk (NO) (1002.99 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/no/documents/product-information/respreeza-epar-product-information_no.pdf)

polski (PL) (779.8 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/pl/documents/product-information/respreeza-epar-product-information_pl.pdf)

português (PT) (994.63 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/pt/documents/product-information/respreeza-epar-product-information_pt.pdf)

română (RO) (578.08 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/ro/documents/product-information/respreeza-epar-product-information_ro.pdf)

slovenčina (SK) (717.63 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/sk/documents/product-information/respreeza-epar-product-information_sk.pdf)

slovenščina (SL) (429.8 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/sl/documents/product-information/respreeza-epar-product-information_sl.pdf)

Suomi (FI) (735.95 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/fi/documents/product-information/respreeza-epar-product-information_fi.pdf)

svenska (SV) (686.01 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

27/03/2025

[View](/sv/documents/product-information/respreeza-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000245783 26/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Respreeza : EPAR - All Authorised presentations

English (EN) (16.93 KB - PDF)

**First published:** 16/09/2015

**Last updated:** 26/08/2019

[View](/en/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-601)

български (BG) (38.66 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/bg/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.32 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/es/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.43 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/cs/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.02 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/da/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.05 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/de/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.57 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/et/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (42.75 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/el/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_el.pdf)

français (FR) (17.48 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/fr/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.54 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/hr/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.04 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/is/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.66 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/it/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.56 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/lv/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.45 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/lt/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.41 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/hu/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (33.66 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/mt/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (17.59 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/nl/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.49 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/no/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.72 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/pl/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.72 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/pt/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.29 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/ro/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.27 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/sk/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.28 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/sl/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (26.26 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/fi/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.6 KB - PDF)

**First published:**

16/09/2015

**Last updated:**

26/08/2019

[View](/sv/documents/all-authorised-presentations/respreeza-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Respreeza Active substance human alpha1-proteinase inhibitor International non-proprietary name (INN) or common name alpha1-proteinase inhibitor (human) Therapeutic area (MeSH)

- Genetic Diseases, Inborn
- Lung Diseases

Anatomical therapeutic chemical (ATC) code B02AB02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.

## Authorisation details

EMA product number EMEA/H/C/002739 Marketing authorisation holder

CSL Behring GmbH

Emil-von-Behring-Straße 76

Opinion adopted 25/06/2015 Marketing authorisation issued 20/08/2015 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Respreeza : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.65 KB - PDF)

**First published:** 27/03/2025

[View](/en/documents/procedural-steps-after/respreeza-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Respreeza : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (256.43 KB - PDF)

**First published:** 03/10/2016

**Last updated:** 01/04/2025

[View](/en/documents/procedural-steps-after/respreeza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Respreeza : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/76739/2015

English (EN) (2.38 MB - PDF)

**First published:** 16/09/2015

**Last updated:** 16/09/2015

[View](/en/documents/assessment-report/respreeza-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Respreeza

Adopted

Reference Number: EMA/CHMP/76738/2015

English (EN) (69.34 KB - PDF)

**First published:** 26/06/2015

**Last updated:** 26/06/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-respreeza_en.pdf)

#### News on Respreeza

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2015) 26/06/2015

#### More information on Respreeza

- [Respreeza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/respreeza)
- [Respreeza - supply shortage](/en/medicines/human/shortages/respreeza)
- [Respreeza - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/respreeza-0)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/03/2025

## Share this page

[Back to top](#main-content)